Table 5 The antiviral efficacy of (+)-usnic acid and controls against the SARS-CoV-2 variants [Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2)].
Compounds | (+)-Usnic Acid | Chloroquine | Remdesivir | Lopinavir | |||||
|---|---|---|---|---|---|---|---|---|---|
Variants | IC50 (μM) | CC50 (μM) | SI | IC50 (μM) | CC50 (μM) | IC50 (μM) | CC50 (μM) | IC50 (μM) | CC50 (μM) |
SARS-CoV-2 Alpha var (B.1.1.7) | 6.05 (SE ± 0.33) | 34.8 (SE ± 1.9) | 5.8 | 6.16 (SE ± 0.30) | > 150 | 2.25 (SE ± 0.16) | > 50 | 10.8 (SE ± 0.9) | > 50 |
SARS-CoV-2 Beta var (B.1.351) | 2.92 (SE ± 0.06) | 32.4 (SE ± 1.0) | 11.1 | 2.64 (SE ± 0.49) | > 150 | 1.47 (SE ± 0.16) | > 50 | 11.8 (SE ± 0.5) | > 50 |
SARS-CoV-2 Delta var (B.1.617.2) | 7.17 (SE ± 0.59) | > 50 | 6.97 | 6.22 (SE ± 0.34) | > 150 | 6.48 (SE ± 0.40) | > 50 | 15.3 (SE ± 5.6) | > 50 |
